drugset
Drugs / Lumicitabine
last change Oct 2020 re-read 9 days ago

Lumicitabine

also known as ALS-008176 · Als-8176 · JNJ-64041575 · Lumicitabina

Small molecule

Developed for
respiratory syncytial virus infectious disease · Mononegavirales infectious disease
Investigated by
Janssen Research & Development, LLC · Alios Biopharma Inc. · Janssen Pharmaceutical K.K.

Trials 14

today NCT03502694 · Ph 2 NCT03468777 · Ph 1 NCT03441529 · Ph 1 NCT03332459 · Ph 2 NCT03333317 · Ph 2 NCT02935673 · Ph 2 NCT02813460 · Ph 1 NCT02833831 · Ph 1 NCT02673476 · Ph 2 NCT02478333 · Ph 1 NCT02231671 · Ph 1 NCT02202356 · Ph 1 NCT02094365 · Ph 2 NCT01906164 · Ph 1
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 18 trials
Phase 1 NCT03468777 Mar → Jul 2018 — Janssen Research & Development, LLC Terminated No outcome recorded
Phase 1 NCT03441529 Feb → May 2018 — Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT02833831 Jun 2016 → Feb 2017 — Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT02813460 Jun → Aug 2016 — Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT02478333 May → Jul 2015 respiratory syncytial virus infectious disease Janssen Pharmaceutical K.K. Completed No outcome recorded
Phase 1 NCT02231671 Aug → Sep 2014 respiratory syncytial virus infectious disease Alios Biopharma Inc. Completed No outcome recorded
Phase 1 NCT02202356 Jul 2014 → Feb 2018 respiratory syncytial virus infectious disease Alios Biopharma Inc. Completed No outcome recorded
Phase 1 NCT01906164 May → Nov 2013 respiratory syncytial virus infectious disease Alios Biopharma Inc. Completed No outcome recorded
Phase 26 trials · 2 missed
Phase 2 NCT03502694 Nov 2018 → Apr 2019 Mononegavirales infectious disease Janssen Research & Development, LLC Withdrawn No outcome recorded Stop: Business
Phase 2 NCT03332459 Jan 2018 → Apr 2020 respiratory syncytial virus infectious disease Janssen Research & Development, LLC Completed No outcome recorded
Phase 2 NCT03333317 Nov 2017 → Mar 2018 respiratory syncytial virus infectious disease Janssen Research & Development, LLC Terminated Missed primary Stop: Business
Phase 2 NCT02935673 Oct 2016 → Jul 2018 respiratory syncytial virus infectious disease Janssen Research & Development, LLC Terminated Missed primary Stop: Business
Phase 2 NCT02673476 Feb → Oct 2016 respiratory syncytial virus infectious disease Alios Biopharma Inc. Completed No outcome recorded
Phase 2 NCT02094365 Mar → Jun 2014 respiratory syncytial virus infectious disease Alios Biopharma Inc. Completed No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2015-11-18 Janssen Research & Development, LLC Results New Data Published In The New England Journal Of Medicine Shows Potential Of Compound To Fight RSV Infection In Adults And Children jnj.com ↗

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 16 sources stand behind the page.

FieldValueCited text
Known as Lumicitabine ClinicalTrials.gov intervention name — accepted as the source's own label NCT03502694 ↗
5

NCT03332459 ↗

NCT02935673 ↗

NCT03333317 ↗

NCT03441529 ↗

NCT03468777 ↗
Known as ALS-008176 “treatment of RSV-infected infants/children with lumicitabine (also known as JNJ-64041575 or ALS-008176) will decrease subsequent wheezing/asthma compared to placebo” NCT03332459 ↗
8

NCT01906164 ↗

NCT02478333 ↗

NCT02673476 ↗

NCT02202356 ↗

NCT02833831 ↗

NCT02813460 ↗

NCT02094365 ↗

NCT02231671 ↗
Known as Als-8176 ChEMBL registry synonym — accepted as the source's own label CHEMBL3417258 ↗
Known as JNJ-64041575 “treatment of RSV-infected infants/children with lumicitabine (also known as JNJ-64041575 or ALS-008176) will decrease subsequent wheezing/asthma compared to placebo” NCT03332459 ↗
Known as Lumicitabina ChEMBL registry synonym — accepted as the source's own label CHEMBL3417258 ↗
Modality Small molecule “Participants received the oral nucleoside analogue ALS-008176 or placebo 12 hours after confirmation of RSV infection or 6 days after inoculation.” PMID 26580997 ↗ Nov 2015
Route Oral “orally administered ALS-008176” NCT01906164 ↗